{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T18:44:28Z","timestamp":1791312268835,"version":"4.3.1"},"reference-count":47,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,7,20]],"date-time":"2026-07-20T00:00:00Z","timestamp":1784505600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,7,20]],"date-time":"2026-07-20T00:00:00Z","timestamp":1784505600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"National Natural Science Foundation of China (NSFC) projects","award":["82574610"],"award-info":[{"award-number":["82574610"]}]},{"name":"National Natural Science Foundation of China (NSFC) projects","award":["82430121"],"award-info":[{"award-number":["82430121"]}]},{"name":"National Natural Science Foundation of China (NSFC) projects","award":["82574792"],"award-info":[{"award-number":["82574792"]}]},{"name":"National Science and Technology Major Project for Prevention and Treatment Research of Cancer, Cardio-cerebrovascular, Respiratory and Metabolic Diseases","award":["2023ZD0502706"],"award-info":[{"award-number":["2023ZD0502706"]}]},{"name":"Youth Talent Lifting Project of China Association of Chinese Medicine","award":["2024-QNRC2-B22"],"award-info":[{"award-number":["2024-QNRC2-B22"]}]},{"name":"Special Project for Technological Innovation in New Productive Forces of Modern Chinese Medicines","award":["No. 24ZXZKSY00050"],"award-info":[{"award-number":["No. 24ZXZKSY00050"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Chin Med"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Heart failure with preserved ejection fraction (HFpEF) has currently emerged as a predominant and challenging subtype of heart failure, with high morbidity and mortality. However, the efficacy of current therapeutic strategies for HFpEF remains unsatisfactory. The traditional Chinese medicine formulation Shenfu Qiangxin pill (SFQX) ameliorates clinical symptoms in patients with heart failure, but its precise mechanisms for HFpEF remain to be elucidated. This study aimed to investigate the therapeutic potential of SFQX for HFpEF and to elucidate the mechanisms underlying its effects.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>UPLC-Q-TOF-MS\/MS analysis was performed to identify the major active ingredients of SFQX. The HFpEF mouse model was established using a high-fat diet and an N\u03c9-Nitro-L-arginine methyl ester hydrochloride (L-NAME) to evaluate the therapeutic efficacy of SFQX. We employed an integrated approach combining single-cell RNA sequencing (scRNA-seq) with functional and molecular validation to characterize SFQX-induced changes in cardiac cellular composition, cell-state remodeling, and tissue-level phenotypes in HFpEF.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>We show that SFQX exerts therapeutic effects against HFpEF by coordinately modulating maladaptive cardiac cell subsets. Specifically, SFQX was associated with reprogramming of pathogenic immune cell polarization, normalization of fibroblast state heterogeneity, enhanced endothelial metabolic adaptability, and restoration of lymphatic endothelial homeostasis. These multicellular changes were accompanied by improved cardiac structure and function, reduced fibrosis and inflammation, enhanced lymphatic drainage capacity, and alleviated myocardial edema.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Our findings highlight the ability of SFQX, as a multicomponent agent, to precisely regulate the highly heterogeneous pathology of HFpEF at a network level. This work not only establishes a mechanistic link between holistic principles of traditional medicine and modern biology but also provides a novel theoretical basis for SFQX's efficacy in multifactorial diseases.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s13020-026-01456-3","type":"journal-article","created":{"date-parts":[[2026,7,20]],"date-time":"2026-07-20T03:47:01Z","timestamp":1784519221000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Single-cell transcriptomics reveals how Shenfu Qiangxin pill ameliorates HFpEF by modulating cardiac cellular heterogeneity"],"prefix":"10.1186","volume":"21","author":[{"given":"Yakun","family":"Yang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Haohao","family":"Gao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhifei","family":"Fu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Weiying","family":"Hu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yijing","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Haixia","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hanqing","family":"Lin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aodi","family":"Fan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ke","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jingyu","family":"Ni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guanwei","family":"Fan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lan","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,7,20]]},"reference":[{"issue":"10431","key":"1456_CR1","doi-asserted-by":"publisher","first-page":"1083","DOI":"10.1016\/S0140-6736(23)02756-3","volume":"403","author":"P Campbell","year":"2024","unstructured":"Campbell P, Rutten FH, Lee MM, Hawkins NM, Petrie MC. Heart failure with preserved ejection fraction: everything the clinician needs to know. Lancet. 2024;403(10431):1083\u201392.","journal-title":"Lancet"},{"issue":"6","key":"1456_CR2","doi-asserted-by":"publisher","first-page":"400","DOI":"10.1038\/s41569-020-00480-6","volume":"18","author":"S Mishra","year":"2021","unstructured":"Mishra S, Kass DA. Cellular and molecular pathobiology of heart failure with preserved ejection fraction. Nat Rev Cardiol. 2021;18(6):400\u201323.","journal-title":"Nat Rev Cardiol"},{"issue":"6","key":"1456_CR3","doi-asserted-by":"publisher","first-page":"379","DOI":"10.1161\/CIRCULATIONAHA.123.067504","volume":"151","author":"Y Yamada","year":"2025","unstructured":"Yamada Y, Sadahiro T, Nakano K, Honda S, Abe Y, Akiyama T, et al. Cardiac reprogramming and gata4 overexpression reduce fibrosis and improve diastolic dysfunction in heart failure with preserved ejection fraction. Circulation. 2025;151(6):379\u201395.","journal-title":"Circulation"},{"issue":"1","key":"1456_CR4","doi-asserted-by":"publisher","first-page":"265","DOI":"10.1186\/s12933-025-02774-w","volume":"24","author":"E Gorica","year":"2025","unstructured":"Gorica E, Geiger MA, Di Venanzio L, Atzemian N, Kleeberger JA, Grigorian D, et al. Cardiometabolic heart failure with preserved ejection fraction: from molecular signatures to personalized treatment. Cardiovasc Diabetol. 2025;24(1):265.","journal-title":"Cardiovasc Diabetol"},{"issue":"8","key":"1456_CR5","first-page":"1424","volume":"40","author":"K Gharagozloo","year":"2024","unstructured":"Gharagozloo K, Mehdizadeh M, Heckman G, Rose RA, Howlett J, Howlett SE, et al. Heart failure with preserved ejection rraction in the elderly population: basic mechanisms and clinical considerations. Can J Cardiol. 2024;40(8):1424\u201344.","journal-title":"Can J Cardiol"},{"issue":"13","key":"1456_CR6","doi-asserted-by":"publisher","DOI":"10.1161\/JAHA.124.040100","volume":"14","author":"W Ni","year":"2025","unstructured":"Ni W, Chen X, Guo K, Ni Q, Lin K, Jiang R, et al. Prevalence and prognostic value of the novel consensus definition of metabolic hyperferritinemia in patients with heart failure with preserved ejection fraction across different glucose metabolism states. J Am Heart Assoc. 2025;14(13):e040100.","journal-title":"J Am Heart Assoc"},{"issue":"3","key":"1456_CR7","doi-asserted-by":"publisher","first-page":"211","DOI":"10.1038\/s44161-022-00032-w","volume":"1","author":"GG Schiattarella","year":"2022","unstructured":"Schiattarella GG, Alcaide P, Condorelli G, Gillette TG, Heymans S, Jones EAV, et al. Immunometabolic mechanisms of heart failure with preserved ejection fraction. Nat Cardiovasc Res. 2022;1(3):211\u201322.","journal-title":"Nat Cardiovasc Res"},{"key":"1456_CR8","doi-asserted-by":"publisher","first-page":"215","DOI":"10.1016\/j.jare.2024.02.006","volume":"68","author":"G Li","year":"2025","unstructured":"Li G, Zhao H, Cheng Z, Liu J, Li G, Guo Y. Single-cell transcriptomic profiling of heart reveals ANGPTL4 linking fibroblasts and angiogenesis in heart failure with preserved ejection fraction. J Adv Res. 2025;68:215\u201330.","journal-title":"J Adv Res"},{"issue":"1","key":"1456_CR9","doi-asserted-by":"publisher","first-page":"1436","DOI":"10.1038\/s42003-025-08827-w","volume":"8","author":"X Xiao","year":"2025","unstructured":"Xiao X, Wu W, Mao Q, Li B, Wang J, Liu S, et al. Single-cell transcriptomic profiling reveals cell type heterogeneity between HFpEF and HFrEF. Commun Biol. 2025;8(1):1436.","journal-title":"Commun Biol"},{"issue":"19","key":"1456_CR10","doi-asserted-by":"publisher","first-page":"1517","DOI":"10.1161\/CIRCULATIONAHA.122.062984","volume":"150","author":"C Panico","year":"2024","unstructured":"Panico C, Felicetta A, Kunderfranco P, Cremonesi M, Salvarani N, Carullo P, et al. Single-cell RNA sequencing reveals metabolic stress-dependent activation of cardiac macrophages in a model of dyslipidemia-induced diastolic dysfunction. Circulation. 2024;150(19):1517\u201332.","journal-title":"Circulation"},{"issue":"6","key":"1456_CR11","doi-asserted-by":"publisher","first-page":"1001","DOI":"10.1007\/s00395-024-01074-w","volume":"119","author":"JD Lanzer","year":"2024","unstructured":"Lanzer JD, Wienecke LM, Ramirez Flores RO, Zylla MM, Kley C, Hartmann N, et al. Single-cell transcriptomics reveal distinctive patterns of fibroblast activation in heart failure with preserved ejection fraction. Basic Res Cardiol. 2024;119(6):1001\u201328.","journal-title":"Basic Res Cardiol"},{"key":"1456_CR12","doi-asserted-by":"publisher","DOI":"10.1016\/j.phymed.2025.156828","volume":"143","author":"J Hao","year":"2025","unstructured":"Hao J, Wang M, Wu Q, Song T, Hao Y, Chang L, et al. Deciphering the molecular mechanisms of QLQX capsules in heart failure: a multi-omics perspective. Phytomedicine. 2025;143:156828.","journal-title":"Phytomedicine"},{"issue":"3","key":"1456_CR13","doi-asserted-by":"publisher","first-page":"196","DOI":"10.1097\/HM9.0000000000000046","volume":"2","author":"X Li","year":"2022","unstructured":"Li X, Wichai N, Wang J, Liu X, Yan H, Wang Y, et al. Regulation of innate and adaptive immunity using herbal medicine: benefits for the COVID-19 vaccination. Acupuncture Herbal Medicine. 2022;2(3):196\u2013206.","journal-title":"Acupuncture Herbal Medicine"},{"issue":"15","key":"1456_CR14","doi-asserted-by":"publisher","DOI":"10.1097\/MD.0000000000024531","volume":"100","author":"L Ren","year":"2021","unstructured":"Ren L, Guan H, Dai G, Gao W, Su J. Efficacy and safety of Shenfuqiangxin pills in complementary treatment of chronic heart failure: A protocol for systematic review and meta-analysis. Medicine (Baltimore). 2021;100(15):e24531.","journal-title":"Medicine (Baltimore)"},{"issue":"21","key":"1456_CR15","doi-asserted-by":"publisher","DOI":"10.1097\/MD.0000000000020271","volume":"99","author":"L Guo","year":"2020","unstructured":"Guo L, Yuan H, Zhang D, Zhang J, Hua Q, Ma X, et al. A multi-center, randomized, double-blind, placebo-parallel controlled trial for the efficacy and safety of shenfuqiangxin pills in the treatment of chronic heart failure (Heart-Kidney yang deficiency syndrome). Medicine (Baltimore). 2020;99(21):e20271.","journal-title":"Medicine (Baltimore)"},{"issue":"6","key":"1456_CR16","doi-asserted-by":"publisher","first-page":"553","DOI":"10.3892\/etm.2021.9985","volume":"21","author":"S Zhang","year":"2021","unstructured":"Zhang S, Zhang Y, Wang X, Wu L, Shen J, Gu M, et al. Effects of Shenfu Qiangxin Drink on H(2)O(2)-induced oxidative stress, inflammation and apoptosis in neonatal rat cardiomyocytes and possible underlying mechanisms. Exp Ther Med. 2021;21(6):553.","journal-title":"Exp Ther Med"},{"issue":"7752","key":"1456_CR17","doi-asserted-by":"publisher","first-page":"351","DOI":"10.1038\/s41586-019-1100-z","volume":"568","author":"GG Schiattarella","year":"2019","unstructured":"Schiattarella GG, Altamirano F, Tong D, French KM, Villalobos E, Kim SY, et al. Nitrosative stress drives heart failure with preserved ejection fraction. Nature. 2019;568(7752):351\u20136.","journal-title":"Nature"},{"issue":"12","key":"1456_CR18","doi-asserted-by":"publisher","first-page":"2943","DOI":"10.1161\/ATVBAHA.121.316707","volume":"41","author":"L Qin","year":"2021","unstructured":"Qin L, Zhang H, Li B, Jiang Q, Lopez F, Min W, et al. CCM3 loss-induced lymphatic defect is mediated by the augmented VEGFR3-ERK1\/2 signaling. Arterioscler Thromb Vasc Biol. 2021;41(12):2943\u201360.","journal-title":"Arterioscler Thromb Vasc Biol"},{"issue":"23","key":"1456_CR19","doi-asserted-by":"publisher","DOI":"10.1002\/advs.202500610","volume":"12","author":"C Ma","year":"2025","unstructured":"Ma C, Hua Y, Yang S, Zhao Y, Zhang W, Miao Y, et al. Wogonin attenuates atherosclerosis via KLF11-mediated suppression of PPARalpha-YAP1-driven glycolysis and enhancement of ABCA1\/G1-mediated cholesterol efflux. Adv Sci (Weinh). 2025;12(23):e2500610.","journal-title":"Adv Sci (Weinh)"},{"issue":"1","key":"1456_CR20","doi-asserted-by":"publisher","first-page":"1352","DOI":"10.1038\/s41467-024-45440-7","volume":"15","author":"S Ranjbarvaziri","year":"2024","unstructured":"Ranjbarvaziri S, Zeng A, Wu I, Greer-Short A, Farshidfar F, Budan A, et al. Targeting HDAC6 to treat heart failure with preserved ejection fraction in mice. Nat Commun. 2024;15(1):1352.","journal-title":"Nat Commun"},{"key":"1456_CR21","doi-asserted-by":"publisher","DOI":"10.3390\/biomedicines11082131","author":"JM Inacio","year":"2023","unstructured":"Inacio JM, Cristo F, Pinheiro M, Vasques-Novoa F, Saraiva F, Nunes MM, et al. Myocardial RNA sequencing reveals new potential therapeutic targets in heart failure with preserved ejection fraction. Biomedicines. 2023. https:\/\/doi.org\/10.3390\/biomedicines11082131.","journal-title":"Biomedicines"},{"issue":"2","key":"1456_CR22","doi-asserted-by":"publisher","first-page":"174","DOI":"10.1016\/j.jacbts.2022.08.003","volume":"8","author":"H Liu","year":"2023","unstructured":"Liu H, Huang Y, Zhao Y, Kang GJ, Feng F, Wang X, et al. Inflammatory Macrophage Interleukin-1beta mediates high-fat diet-induced heart failure with preserved ejection fraction. JACC Basic Transl Sci. 2023;8(2):174\u201385.","journal-title":"JACC Basic Transl Sci"},{"key":"1456_CR23","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.946832","volume":"13","author":"JH Wen","year":"2022","unstructured":"Wen JH, Li DY, Liang S, Yang C, Tang JX, Liu HF. Macrophage autophagy in macrophage polarization, chronic inflammation and organ fibrosis. Front Immunol. 2022;13:946832.","journal-title":"Front Immunol"},{"issue":"5","key":"1456_CR24","doi-asserted-by":"publisher","first-page":"664","DOI":"10.1161\/CIRCRESAHA.125.326236","volume":"137","author":"T Venkatesan","year":"2025","unstructured":"Venkatesan T, Toumpourleka M, Niewiadomska M, Farhat K, Morris L, Elkholey K, et al. Vagal stimulation rescues HFpEF by altering cardiac resident macrophage function. Circ Res. 2025;137(5):664\u201381.","journal-title":"Circ Res"},{"issue":"11","key":"1456_CR25","doi-asserted-by":"publisher","first-page":"42706","DOI":"10.31083\/FBL42706","volume":"30","author":"Y Li","year":"2025","unstructured":"Li Y, Chen H, Zhou S. Macrophages and tissue homeostasis: From physiological functions to disease onset. Front Biosci (Landmark Ed). 2025;30(11):42706.","journal-title":"Front Biosci (Landmark Ed)"},{"issue":"2","key":"1456_CR26","doi-asserted-by":"publisher","first-page":"40","DOI":"10.32607\/actanaturae.11154","volume":"12","author":"AG Ovchinnikov","year":"2020","unstructured":"Ovchinnikov AG, Arefieva TI, Potekhina AV, Filatova AY, Ageev FT, Boytsov SA. The molecular and cellular mechanisms associated with a microvascular inflammation in the pathogenesis of heart failure with preserved ejection fraction. Acta Naturae. 2020;12(2):40\u201351.","journal-title":"Acta Naturae"},{"issue":"10","key":"1456_CR27","doi-asserted-by":"publisher","DOI":"10.15252\/emmm.201910865","volume":"12","author":"M Sweeney","year":"2020","unstructured":"Sweeney M, Corden B, Cook SA. Targeting cardiac fibrosis in heart failure with preserved ejection fraction: mirage or miracle? EMBO Mol Med. 2020;12(10):e10865.","journal-title":"EMBO Mol Med"},{"issue":"6","key":"1456_CR28","doi-asserted-by":"publisher","first-page":"1092","DOI":"10.1161\/HYPERTENSIONAHA.117.09045","volume":"69","author":"A Takawale","year":"2017","unstructured":"Takawale A, Zhang P, Patel VB, Wang X, Oudit G, Kassiri Z. Tissue inhibitor of matrix metalloproteinase-1 promotes myocardial fibrosis by mediating CD63-integrin beta1 interaction. Hypertension. 2017;69(6):1092\u2013103.","journal-title":"Hypertension"},{"issue":"25","key":"1456_CR29","doi-asserted-by":"publisher","DOI":"10.1126\/sciadv.adk8501","volume":"10","author":"R Patrick","year":"2024","unstructured":"Patrick R, Janbandhu V, Tallapragada V, Tan SSM, McKinna EE, Contreras O, et al. Integration mapping of cardiac fibroblast single-cell transcriptomes elucidates cellular principles of fibrosis in diverse pathologies. Sci Adv. 2024;10(25):eadk8501.","journal-title":"Sci Adv"},{"issue":"1","key":"1456_CR30","doi-asserted-by":"publisher","first-page":"62","DOI":"10.1186\/s12933-025-02623-w","volume":"24","author":"MOJ Grootaert","year":"2025","unstructured":"Grootaert MOJ, Pasut A, Raman J, Simmonds SJ, Callewaert B, Col U, et al. Mural cell dysfunction contributes to diastolic heart failure by promoting endothelial dysfunction and vessel remodelling. Cardiovasc Diabetol. 2025;24(1):62.","journal-title":"Cardiovasc Diabetol"},{"key":"1456_CR31","doi-asserted-by":"publisher","DOI":"10.1242\/dev.199906","author":"FC Simoes","year":"2022","unstructured":"Simoes FC, Riley PR. Immune cells in cardiac repair and regeneration. Development. 2022. https:\/\/doi.org\/10.1242\/dev.199906.","journal-title":"Development"},{"key":"1456_CR32","doi-asserted-by":"publisher","DOI":"10.15420\/cfr.2022.06","volume":"8","author":"K Teramoto","year":"2022","unstructured":"Teramoto K, Teng TK, Chandramouli C, Tromp J, Sakata Y, Lam CS. Epidemiology and clinical features of heart failure with preserved ejection fraction. Card Fail Rev. 2022;8:e27.","journal-title":"Card Fail Rev"},{"issue":"11","key":"1456_CR33","doi-asserted-by":"publisher","first-page":"38864","DOI":"10.31083\/FBL38864","volume":"30","author":"R Su","year":"2025","unstructured":"Su R, Song L, Liu Y, Zhang C, Xie L, Han Z. Macrophage-fibroblast crosstalk in fibrosis: key regulator of fibrosis across different organs. Front Biosci (Landmark Ed). 2025;30(11):38864.","journal-title":"Front Biosci (Landmark Ed)"},{"key":"1456_CR34","doi-asserted-by":"crossref","unstructured":"Zanders L, Glaser SF, Ruz Jurado M, Brandt M, John D, Nicin L, Rodriguez Morales D, Abplanalp WT, Procida-Kowalski T, Gan\u00df F, Ullrich E. Deciphering human heart failure with preserved ejection fraction (HFpEF) at single cell resolution. bioRxiv. 2025 3:2025-04.","DOI":"10.1101\/2025.04.02.646923"},{"key":"1456_CR35","doi-asserted-by":"publisher","first-page":"1461073","DOI":"10.3389\/fcvm.2024.1461073","volume":"11","author":"Z Fu","year":"2024","unstructured":"Fu Z, Liu P, Gao X, Shi S, Li Y, Zhang B, et al. Association of systemic inflammatory markers with clinical adverse prognosis and outcomes in HFpEF: a systematic review and meta-analysis of cohort studies. Front Cardiovasc Med. 2024;11:1461073.","journal-title":"Front Cardiovasc Med"},{"issue":"1","key":"1456_CR36","doi-asserted-by":"publisher","first-page":"192","DOI":"10.1186\/s12933-025-02720-w","volume":"24","author":"YJ Song","year":"2025","unstructured":"Song YJ, Zhao XY, Wang LJ, Ning T, Chen MT, Liu P, et al. Epicardial adipose tissue and heterogeneity parameters combined with inflammatory cells to predict the value of heart failure with preserved ejection fraction patients post myocardial infarction. Cardiovasc Diabetol. 2025;24(1):192.","journal-title":"Cardiovasc Diabetol"},{"issue":"22","key":"1456_CR37","doi-asserted-by":"publisher","first-page":"2196","DOI":"10.1016\/j.jacc.2024.02.056","volume":"83","author":"FGP Welt","year":"2024","unstructured":"Welt FGP, Batchelor W, Spears JR, Penna C, Pagliaro P, Ibanez B, et al. Reperfusion Injury in patients with acute myocardial infarction: JACC scientific statement. J Am Coll Cardiol. 2024;83(22):2196\u2013213.","journal-title":"J Am Coll Cardiol"},{"issue":"6","key":"1456_CR38","doi-asserted-by":"publisher","first-page":"735","DOI":"10.1016\/j.jacc.2020.05.076","volume":"76","author":"E Brakenhielm","year":"2020","unstructured":"Brakenhielm E, Gonzalez A, Diez J. Role of Cardiac lymphatics in myocardial edema and fibrosis: JACC review topic of the week. J Am Coll Cardiol. 2020;76(6):735\u201344.","journal-title":"J Am Coll Cardiol"},{"issue":"15","key":"1456_CR39","doi-asserted-by":"publisher","first-page":"1484","DOI":"10.1161\/CIRCULATIONAHA.115.020143","volume":"133","author":"O Henri","year":"2016","unstructured":"Henri O, Pouehe C, Houssari M, Galas L, Nicol L, Edwards-L\u00e9vy F, et al. Selective stimulation of cardiac lymphangiogenesis reduces myocardial edema and fibrosis leading to improved cardiac function following myocardial infarction. Circulation. 2016;133(15):1484\u201397.","journal-title":"Circulation"},{"issue":"2","key":"1456_CR40","doi-asserted-by":"publisher","first-page":"231","DOI":"10.1007\/s00395-025-01159-0","volume":"121","author":"L Hao","year":"2026","unstructured":"Hao L, Li BQ, Zhao FY, Wang JM, Du ZX, Wang HQ. Cardiac lymphatics: functional plasticity in development, disease, and precision-targeted therapies. Basic Res Cardiol. 2026;121(2):231\u201348.","journal-title":"Basic Res Cardiol"},{"key":"1456_CR41","doi-asserted-by":"publisher","DOI":"10.3892\/ijmm.2024.5359","author":"L Bai","year":"2024","unstructured":"Bai L, Wang Y, Du S, Si Y, Chen L, Li L, et al. Lymphangiogenesis: a new strategy for heart disease treatment (review). Int J Mol Med. 2024. https:\/\/doi.org\/10.3892\/ijmm.2024.5359.","journal-title":"Int J Mol Med"},{"issue":"1","key":"1456_CR42","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1038\/s41569-018-0087-8","volume":"16","author":"E Brakenhielm","year":"2019","unstructured":"Brakenhielm E, Alitalo K. Cardiac lymphatics in health and disease. Nat Rev Cardiol. 2019;16(1):56\u201368.","journal-title":"Nat Rev Cardiol"},{"key":"1456_CR43","doi-asserted-by":"publisher","DOI":"10.1038\/s41569-026-01271-1","author":"E Brakenhielm","year":"2026","unstructured":"Brakenhielm E. Cardiac lymphatic dysfunction and repair in cardiovascular disease. Nat Rev Cardiol. 2026. https:\/\/doi.org\/10.1038\/s41569-026-01271-1.","journal-title":"Nat Rev Cardiol"},{"issue":"23","key":"1456_CR44","doi-asserted-by":"publisher","first-page":"1651","DOI":"10.1161\/CIRCULATIONAHA.124.071741","volume":"151","author":"X Guo","year":"2025","unstructured":"Guo X, Huang C, Zhang L, Hu G, Du Y, Chen X, et al. Lymphatic endothelial branched-chain amino acid catabolic defects undermine cardiac lymphatic integrity and drive HFpEF. Circulation. 2025;151(23):1651\u201366.","journal-title":"Circulation"},{"issue":"24","key":"1456_CR45","doi-asserted-by":"publisher","first-page":"2817","DOI":"10.1016\/j.jacc.2020.10.022","volume":"76","author":"G Rossitto","year":"2020","unstructured":"Rossitto G, Mary S, McAllister C, Neves KB, Haddow L, Rocchiccioli JP, et al. Reduced lymphatic reserve in heart failure with preserved ejection fraction. J Am Coll Cardiol. 2020;76(24):2817\u201329.","journal-title":"J Am Coll Cardiol"},{"issue":"4","key":"1456_CR46","doi-asserted-by":"publisher","first-page":"263","DOI":"10.1016\/j.jacc.2013.02.092","volume":"62","author":"WJ Paulus","year":"2013","unstructured":"Paulus WJ, Tschope C. A novel paradigm for heart failure with preserved ejection fraction: comorbidities drive myocardial dysfunction and remodeling through coronary microvascular endothelial inflammation. J Am Coll Cardiol. 2013;62(4):263\u201371.","journal-title":"J Am Coll Cardiol"},{"issue":"1","key":"1456_CR47","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1097\/HM9.0000000000000003","volume":"1","author":"Z Du","year":"2021","unstructured":"Du Z, Shu Z, Li C, Song X, Ma X, Liao L, et al. Baoyuan decoction alleviates myocardial infarction through the regulation of metabolic dysfunction and the mitochondria-dependent caspase-9\/3 pathway. Acupuncture Herbal Med. 2021;1(1):49\u201358.","journal-title":"Acupuncture Herbal Med"}],"container-title":["Chinese Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13020-026-01456-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13020-026-01456-3","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13020-026-01456-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,20]],"date-time":"2026-07-20T05:02:03Z","timestamp":1784523723000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s13020-026-01456-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,20]]},"references-count":47,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["1456"],"URL":"https:\/\/doi.org\/10.1186\/s13020-026-01456-3","relation":{},"ISSN":["1749-8546"],"issn-type":[{"value":"1749-8546","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,20]]},"assertion":[{"value":"4 February 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 June 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 July 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The animal study was approved by the Animal Care Committee of Tianjin University of Traditional Chinese Medicine (Approval No. TCM-LAEC2024135F1127).","order":1,"name":"Ethics","label":"Ethics approval and consent to participate","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"All authors consent to publish this manuscript.","order":2,"name":"Ethics","label":"Consent for publication","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":3,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Declarations"}}],"article-number":"199"}}